DK0601052T3 - Terapeutisk fremgangsmåde til behandling af IDDM - Google Patents

Terapeutisk fremgangsmåde til behandling af IDDM

Info

Publication number
DK0601052T3
DK0601052T3 DK92918792.0T DK92918792T DK0601052T3 DK 0601052 T3 DK0601052 T3 DK 0601052T3 DK 92918792 T DK92918792 T DK 92918792T DK 0601052 T3 DK0601052 T3 DK 0601052T3
Authority
DK
Denmark
Prior art keywords
alpha interferon
neutralizing antibodies
iddm
treatment
therapeutic method
Prior art date
Application number
DK92918792.0T
Other languages
Danish (da)
English (en)
Inventor
Timothy Andrew Stewart
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0601052T3 publication Critical patent/DK0601052T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK92918792.0T 1991-08-30 1992-08-19 Terapeutisk fremgangsmåde til behandling af IDDM DK0601052T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75230991A 1991-08-30 1991-08-30

Publications (1)

Publication Number Publication Date
DK0601052T3 true DK0601052T3 (da) 1996-11-18

Family

ID=25025756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92918792.0T DK0601052T3 (da) 1991-08-30 1992-08-19 Terapeutisk fremgangsmåde til behandling af IDDM

Country Status (8)

Country Link
EP (1) EP0601052B1 (de)
JP (1) JPH06510061A (de)
AT (1) ATE144149T1 (de)
DE (1) DE69214656T2 (de)
DK (1) DK0601052T3 (de)
ES (1) ES2092698T3 (de)
GR (1) GR3022092T3 (de)
WO (1) WO1993004699A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0725654A1 (de) * 1993-09-17 1996-08-14 Laboratoire Europeen De Biotechnologie S.A. Pharmazeutische zusammensetzung mit monoklonale antikoerpern gegen den interferenrezeptor, mit neutralisierender wirkung gegen typ i interferon
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
WO1998006431A2 (en) * 1996-08-16 1998-02-19 Osther Kurt B Method for treating diabetes
EP1037995A1 (de) 1997-12-08 2000-09-27 Genentech, Inc. Menschliches interferon-epsilon: ein typ 1 interferon
ZA9811070B (en) 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
EP1351707B9 (de) * 2001-01-09 2012-01-25 Baylor Research Institute Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
AU2004232362C1 (en) 2003-04-23 2008-05-29 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CN101155831B (zh) 2005-02-10 2015-08-19 贝勒研究院 抗干扰素α单克隆抗体及其使用方法
AU2006263331B2 (en) 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
CN102083859B (zh) 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon

Also Published As

Publication number Publication date
DE69214656D1 (de) 1996-11-21
JPH06510061A (ja) 1994-11-10
ES2092698T3 (es) 1996-12-01
WO1993004699A1 (en) 1993-03-18
EP0601052B1 (de) 1996-10-16
GR3022092T3 (en) 1997-03-31
EP0601052A1 (de) 1994-06-15
DE69214656T2 (de) 1997-03-13
ATE144149T1 (de) 1996-11-15

Similar Documents

Publication Publication Date Title
DK0601052T3 (da) Terapeutisk fremgangsmåde til behandling af IDDM
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
KR930702026A (ko) 자기항원의 경구 투여에 의한 자기면역 질병의 치료
DK641889A (da) Anvendelse af en blodpladeaktiveringsfaktorantagonist i kombination med monoklonale eller polyklonale antistoffer i et farmaceutisk praeparat til behandling af endotoksisk chok hos pattedyr
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
RU96101193A (ru) Фрагменты антител в терапии
EP1019072A4 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
BR9206398A (pt) Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos
DK77090A (da) Immunmodulerende azaspiraner
ATE107514T1 (de) Stabilisierte protein- oder peptidkonjugate.
ES2074565T3 (es) Empleo de melatonina para tratar el sindrome pre-menstrual.
DK0522091T3 (da) Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose
SK42395A3 (en) Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof
JPH09504792A (ja) 慢性関節リウマチに関する治療
RU96115219A (ru) Способ лечения больных сахарным диабетом
DK0432400T3 (da) Farmakologisk aktiv forbindelse BPC, fremgangsmåde til fremstilling heraf og dens anvendelse indenfor terapien
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
Broad et al. Trypsin fails as Australian snake bite cure
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
SE9704451D0 (sv) New method and compositions for the treatment of autoimmune diseases
KR880001300A (ko) 리트로바이러스 감염의 예방 및 치료를 위한 방법 및 조성물
RU93043512A (ru) Способ лечения крепитирующего тендовагенита предплечья